SUMMARY
Human pyrin with gain-of-function mutations in its B30.2/SPRY domain causes the autoinflammatory disease familial Mediterranean fever by assembling an ASCdependent inflammasome that activates caspase-1. Wildtype human pyrin can also form an inflammasome complex with ASC after engagement by autoinflammatory PSTPIP1 mutants. How the pyrin inflammasome is activated in the absence of disease-associated mutations is not yet known. We report here that ribotoxic stress triggers the assembly of the human pyrin inflammasome leading to ASC oligomerization and caspase-1 activation in THP-1 macrophages, and in a 293T cell line stably reconstituted with components of the pyrin inflammasome. Knockdown of pyrin and selective inhibition of p38 mitogenactivated protein kinase (MAPK) greatly attenuated caspase-1 activation by ribotoxic stress, while expression of the conditional mutant ΔMEKK3:ER* allowed activation of caspase-1 without ribotoxic stress. Disruption of microtubules by colchicine also inhibited pyrin inflammasome activation by ribotoxic stress. Together, our results indicate that ribotoxic stress activates the human pyrin inflammasome through a mechanism that requires p38 MAPK signaling and microtubule stability.
_______________________________________
Pathogens and metabolic danger signals trigger the assembly of cytoplasmic multiprotein complexes termed inflammasomes, which serve as molecular scaffolds for the activation of caspase-1 in innate immune cells (1, 2) . Activated caspase-1 processes the inactive prointerleukin-1β (pro-IL-1β) and pro-interleukin-18 (pro-IL-18) into the active cytokines IL-1β and IL-18, respectively. It is also involved in the unconventional secretion of these cytokines and other proinflammatory mediators such as highmobility group box 1 (HMGB1) (3) . Deregulated inflammasome activity can lead to several autoinflammatory periodic fever syndromes in humans such as Muckle-Wells, familial Mediterranean fever (FMF) and pyogenic arthritis, pyoderma gangrenosum, acne (PAPA) syndromes (4, 5) . This has also been implicated in chronic inflammatory and metabolic diseases such as gout, atherosclerosis, silicosis and type II diabetes (6, 7) .
FMF is caused by mutations in the MEFV gene, which encodes pyrin (8, 9) , but the molecular mechanism by which these mutations lead to increased production of IL-1β is not yet clear. Cell-based reconstitution studies in our laboratory demonstrated that human pyrin can form an inflammasome complex with apoptosisassociated speck-like protein containing a caspase recruitment domain (ASC) and procaspase-1 leading to ASC oligomerization, caspase-1 activation and pro-IL-1β processing (10) . Furthermore, our studies showed that binding of autoinflammatory PAPA-associated proline serine threonine phosphatase-interacting protein 1 (PSTPIP1) mutants to human pyrin could activate the pyrin inflammasome, leading to increased IL-1β production (5) . Based on these studies it was proposed that wildtype pyrin is a pro-inflammatory mediator capable of activating caspase-1, and that FMF-associated pyrin mutations may represent gain-of-function mutations that deregulate pyrin inflammasome activation (10) . In support of this, recent studies in mice have shown that expression of humanized pyrin proteins carrying FMFassociated mutations results in exaggerated IL-1β cytokine production and severe autoinflammation (11) . Despite these recent developments the role of pyrin in the activation of caspase-1 remains unclear.
The p38 mitogen-activated protein kinases (MAPKs) play important roles in various intracellular responses, including proliferation, differentiation, apoptosis, tumorigenesis and inflammation (12) . Activation of p38 MAPKs has been shown to increase production of proinflammatory cytokines, and their specific inhibition potently blocks production of these cytokines and reduces chronic inflammation in inflammatory diseases such as rheumatoid arthritis and inflammatory bowel diseases (13) . The mechanism by which p38 MAPKs increase production of pro-inflammatory cytokines, particularly IL-1β and IL-18, is not fully understood. In this study, we investigated whether p38 MAPKs play a role in the activation of the pyrin inflammasome.
We provide evidence that activation of p38 MAPK by ribotoxic stress can trigger formation of a pyrin inflammasome, resulting in the oligomerization of ASC and subsequent activation of caspase-1.
EXPERIMENTAL PROCEDURES
Antibodies and reagents-Antibodies against caspase-1, pyrin, IL-1β and NLRP3 have been described previously (5, 14, 15) .
Anti-ASC antibody was from Santa Cruz. Anti-phospho p38 and anti-p38 antibodies were from Cell Signaling. Anti-JNK antibody was from BD. Anti-Flag antibody, anisomycin, DON, 4-hydroxytamoxifen (4-HT), colchicine, paclitaxel, nigericin, LPS and cycloheximide were from Sigma. SB203580 and SP600125 were from EMD biosciences. Anti-phospho JNK antibody and recombinant human IFN-γ was from Invitrogen.
The plasmid encoding ΔMEKK3:ER* was a kind gift from SJ Cook (Scotland, UK).
siRNA knockdown-Knockdown of pyrin was performed by transfection of siRNA oligonucleotides targeting human pyrin (Qiagen). Scrambled siRNA (control) or pyrin-specific siRNA was transfected into 293T-C1AP cells or THP-1 cells using Lipofectamine 2000 according to the manufacturer's protocol.
Cell treatments and immunoblot analysis-The
293T-C1AP (293T-caspase-1-ASC-pyrin) and 293T-C1AN (293T-caspase-1-ASC-NLRP3) cells which stably express N-terminally Flagtagged procaspase-1, ASC and pyrin or NLRP3, respectively, were generated by stably transfecting 293T-C1A (293T-caspase-1-ASC) cells with constructs encoding pyrin or NLRP3 as described previously (5, 14, 16) . Cells were treated with the following drugs as indicated in each experiment: anisomycin (20 µM), DON (10 µM), CHX (10 µg/ml), puromycin (8 µg/ml), nigericin (10 µM), SB203580 (20 µM), SP600125 (20 µM), IFNγ (20 ng/mL), LPS (500 ng/ml). Cells were lysed in a buffer containing 20 mM HEPES, pH 7.5, 0.5% NP-40, 50 mM KCl, 150 mM NaCl, 1.5 mM MgCl 2 , 1 mM EGTA and protease inhibitors. Cell lysates were fractionated on SDS-PAGE and then transferred onto PVDF membranes (BioRad). In some experiments, cell culture supernatants were precipitated by methanol/chloroform as described previously (14) and then immunoblotted with appropriate antibodies.
Chemical cross-linking-Chemical cross-linking was performed using discuccinimidyl suberate (DSS, Pierce) as described previously (5, 17, 18) . Briefly, for analysis of pyrin oligomerization, lysates from IFNγ-primed THP-1 cells treated with or without anisomycin were cross-linked with DSS, immunoprecipitated with an antipyrin antibody, and then immunoblotted with an anti-pyrin antibody as described before (5) . For analysis of ASC oligomerization, THP-1 cells were lysed after stimulation, and the cell lysates were centrifuged at 6000 rpm for 10 min. The resulting pellet fractions were resuspended in PBS, cross-linked with DSS and analyzed by immunoblotting with anti-ASC antibody as described before (17,18).
RESULTS

Ribotoxic stress induces pyrin-dependent caspase-1
activation-Molecular evidence suggests that human pyrin forms an inflammasome complex with ASC to activate caspase-1 (5,10).
However, the signaling pathway that engages and activates the pyrin inflammasome is currently unknown. Considering that the p38 MAPK stress-signaling pathway is involved in inflammation and possibly in the activation of caspase-1 in response to stress (13, 19) , we investigated if activation of the p38 MAPK pathway might activate the pyrin inflammasome. To this end, we used a 293T cell line (293T-C1AP) stably reconstituted with the human pyrin inflammasome components pyrin, ASC and procaspase-1 (5). As a control, we used a 293T cell line (293T-C1AN) stably reconstituted with the human NLRP3 inflammasome components NLRP3, ASC and procaspase-1 (5, 14, 16) . The two cell lines were treated with either anisomycin, a ribosome inhibitor that potently activates p38 MAPK and c-Jun N-terminal kinase (JNK) by a "ribotoxic stress response" mechanism (20) , or with nigericin, a pore forming toxin that activates the NLRP3 inflammasome. As shown in Fig. 1A , anisomycin treatment induced robust caspase-1 activation only in the pyrin-expressing 293T-C1AP cells but not in the NLRP3-expressing 293T-C1AN cells, as evidenced by processing of procaspase-1 to the p20 subunit. Similar results were obtained with the mycotoxin deoxynivalenol (DON, vomitoxin), a potent ribosome inhibitor and ribotoxic stress activator (21) (Fig. 1A , third lane). In contrast, the NLRP3 stimulus, nigericin was only able to activate caspase-1 in 293T-C1AN cells, but not in 293T-C1AP cells. Consistent with its well-documented effects (22) , anisomycin induced the activation of both p38 MAPK and JNK in 293T-C1AP cells, as determined by the phosphorylation of each kinase (Fig. 1B) . These results suggest that ribotoxic stress can specifically activate the pyrin inflammasome leading to robust caspase-1 activation.
Ribotoxic stress-induced caspase-1 activation is dependent on p38 MAPK-Since anisomycin induced the activation of both p38 MAPK and JNK in 293T-C1AP cells (Fig. 1B) , we next examined the effect of selective p38 MAPK inhibition on anisomycin-induced caspase-1 activation. Pretreatment with SB203580, which is known to selectively inhibit p38α and p38β MAPKs (13) , significantly reduced caspase-1 activation by anisomycin in 293T-C1AP cells, whereas the selective JNK inhibitor, SP600125, showed little effect ( Fig. 2A and B) . These results indicate that p38 MAPK activity is required for activation of caspase-1 by anisomycin in 293T-C1AP cells. Consistent with these results, ribosome inhibitors that weakly activate p38 (cycloheximide) or do not activate p38 (puromycin) (23), induced significantly less or very little caspase-1 activation, respectively ( Fig. 2C and D) .
To provide further evidence that p38 MAPK is involved in the activation of the pyrin inflammasome, we transfected the 293T-C1AP cells with a construct encoding the conditional protein kinase ΔMEKK3:ER (24). The ΔMEKK3:ER* protein consists of the kinase domain of mitogen-activated protein/ERK kinase kinase 3 (MEKK3) fused in-frame to a modified form of the hormone-binding domain of the estrogen receptor. The ΔMEKK3:ER* protein remains inactive until cells are treated with 4-hydroxytamoxifen (4-HT) allowing activation of the mitogen-activated and stressactivated protein kinases without cellular stress or damage (24) . Similar to the anisomycin effect, treatment of the ΔMEKK3:ER*-expressing 293T-C1AP cells with 4-HT resulted in activation of caspase-1 (Fig. 2E) . Furthermore, selective inhibition of p38 MAPK by SB203580 reduced MEKK3-mediated caspase-1 activation in these cells. No caspase-1 activation was observed after 4-HT stimulation of ΔMEKK3:ER*-expressing 293T-C1A cells, which lack pyrin (Fig. 2F) , indicating that pyrin is required for activation of caspase-1 in response to activation of the ΔMEKK3:ER* protein kinase. Taken together, these observations indicate that p38 MAPK is a critical signaling molecule in the pyrin inflammasome activation pathway.
Knockdown of pyrin reduces caspase-1 activation by anisomycin-To further validate the critical role of pyrin in caspase-1 activation by activated p38 MAPK, we knocked down pyrin expression in 293T-C1AP cells by siRNA (Fig. 3A, lower panel) . As expected, caspase-1 activation by anisomycin was notably reduced in cells transfected with pyrin-specific siRNA, but not in cells transfected with scrambled siRNA (Fig. 3A, upper panel) , indicating that pyrin is indeed required for caspase-1 activation by anisomycin in these cells.
To provide more evidence supporting the role of pyrin in caspase-1 activation by activated p38 MAPK, we treated phorbol-12-myristate-13-acetate (P.M.A)-differentiated THP-1 cells with anisomycin.
Unlike 293T-C1AP cells, anisomycin treatment did not trigger caspase-1 activation in PMA-differentiated THP-1 cells (Fig. 3B, 2 nd lane). We reasoned that this unresponsiveness to anisomycin might be due to the low expression level of pyrin in the PMAdifferentiated THP-1 cells (Fig 3B, lower (Fig.  3C) . Stimulation of the IFNγ-primed THP-1 cells with anisomycin caused caspase-1 activation as observed in 293T-C1AP cells (Fig.  3B, 4 th lane). Knocking down pyrin expression by siRNA in the IFNγ-primed THP-1 cells attenuated caspase-1 activation in response to anisomycin, but not to nigericin (Fig. 3D) .
Collectively, these results demonstrate that the pyrin inflammasome is important for activation of caspase-1 in response to ribotoxic stress in both the pyrin inflammasome-reconstituted 293T-C1AP cells and the human THP-1 macrophage cell line.
Anisomycin facilitates ASC oligomerization-To understand how p38 MAPK activation by anisomycin triggers the pyrin inflammasome assembly, we first determined whether anisomycin could affect the oligomerization status of pyrin. Consistent with our previous published results (5), pyrin was present as a homotrimer in IFNγ-primed THP-1 cells (Fig.  4A) . However, anisomycin treatment did not change the oligomerization status of pyrin, suggesting that anisomycin-induced p38 MAPK signaling acts at the level of ASC recruitment and oligomerization (17). Indeed, by using the ASC oligomerization assay which measures the amount of oligomeric ASC in the NP-40-insoluble low-speed pellets of stimulated cells (17,18), we found a high amount of oligomeric ASC in the pellet fraction of IFNγ plus anisomycin-treated THP-1 cells (Fig. 4B, 3 rd lane), but not in the untreated or IFNγ-treated cells (Fig. 4B, 1 st and 2 nd lanes, respectively). These results, suggest that anisomycin-induced p38 MAPK signaling promotes the recruitment of ASC to the pyrin homotrimer, which facilitates ASC oligomerization.
Destabilization of microtubules inhibits anisomycin-induced caspase-1 activation-
Colchicine, a microtubule destabilizing drug, has been clinically used for the treatment of FMF disease (25) . Although the precise molecular mechanism by which colchicine reduces inflammation in FMF patients remains largely unknown, we have previously demonstrated that both colchicine and nocodazole, each blocked pyrin inflammasome-mediated caspase-1 activation by autoinflammatory PAPAassociated PSTPIP1 mutants (5) . To assess the importance of microtubule polymerization in the anisomycin-induced caspase-1 activation, we stimulated 293T-C1AP cells with anisomycin in the presence or absence of colchicine. As shown in Fig. 4C and D, colchicine almost completely abrogated anisomycin-induced caspase-1 activation. In contrast colchicine treatment significantly increased nigericin-induced caspase-1 activation in 293T-C1AN cells (Fig.  4E and F) . These results indicate that microtubule stability is important for pyrin inflammasome activation, but not for activation of the NLRP3 inflammasome.
DISCUSSION
FMF, is an inherited autoinflammatory disease, caused by missense mutations in human pyrin (8, 9 ). Yet, the exact role of pyrin in inflammation and the signaling pathway(s) that regulate its activity are not fully understood. Earlier studies proposed that pyrin functions as an anti-inflammatory molecule by inhibiting the activity or activation of caspase-1 (26) . However, subsequent studies showed that human pyrin can assemble an inflammasome complex with ASC to activate caspase-1 when coexpressed in HEK-293T cells or when engaged by PAPA-associated PSTPIP1 mutants in HEK-293T and human THP-1 macrophages (5,10). This indicates that pyrin functions as a mediator rather than an inhibitor of caspase-1 activation. This role has been supported by additional studies in macrophages (27) and underscored by knock-in studies in mice expressing humanized pyrin proteins carrying FMF-associated mutations (11) . Using a HEK-293T cell line stably reconstituted with components of the human pyrin inflammasome, and THP-1 macrophages with pyrin knockdown, the present work further supports the role of pyrin as a mediator of caspase-1 activation by demonstrating that ribotoxic stress can activate the human pyrin inflammasome. Several ribosome inhibitors that damage the 28S ribosomal RNA and/or interfere with its functioning can induce a response called "the ribotoxic stress response", which stimulates MAP kinase signaling (20, 23) . Among these anisomycin and the trichothecene mycotoxin DON are two of the most potent ribotoxic stress inducers and activators of the p38 MAPK pathway (23) . Our results demonstrate that these agents, through their ability to activate p38 MAPK, can activate caspase-1 by a pyrindependent mechanism, indicating that p38 MAPK is a critical mediator of pyrin inflammasome activation. The key role of p38 in activation of the pyrin inflammasome was supported by experiments showing that expression of the conditional protein kinase ΔMEKK3:ER* (24), which allows activation of p38 MAPK with 4-HT and without cellular stress or damage, can induce activation of caspase-1 in 293T-C1AP cells. Furthermore, SB203580, a small molecule selective inhibitor of p38 MAPK, can effectively suppress caspase-1 activation by anisomycin and ΔMEKK3:ER*. The regulation of pyrin activity by p38 MAPK suggests that p38 MAPK inhibitors represent potential therapeutics, alone or in combination with colchicine, for the treatment of FMF. The microtubule disrupting drug colchicine is very effective in the treatment of FMF, and the colchicine's responsiveness is an important diagnostic tool for FMF (25, 28) . Our results suggest that this therapeutic benefit of colchicine is likely due to its ability to inhibit the activity of the pyrin inflammasome. Treatment of 293T-C1AP cells with colchicine inhibited pyrinmediated caspase-1 activation in response to anisomycin. In contrast, colchicine treatment had no inhibitory effect on NLRP3-mediated caspase-1 activation in response to nigericin in 293T-C1AN cells. These results indicate that the colchicine responsiveness is highly specific to the pyrin inflammasome pathway and could explain the therapeutic benefit of colchicine in the treatment of FMF. It is not yet clear how colchicine can inhibit the activity of the pyrin inflammasome.
However, since pyrin is associated with microtubules (29), we can speculate that the disruption of microtubules by colchicine might lead to dissociation of pyrin from microtubules. This could prevent pyrin from assembling with ASC and procaspase-1 to form a functional inflammasome. Although colchicine is also effective in the treatment of gouty arthritis, which is mediated by the NLRP3 inflammasome, colchicine does not inhibit the activity of the NLRP3 inflammasome but appears to interfere with the uptake of urate crystals by macrophages (30) . One of the reasons for the controversy regarding pyrin function is the lack of mouse genetic evidence to support a role for mouse pyrin in caspase-1 activation. Mouse pyrin lacks the Cterminal B30.2/SPRY domain, which harbors most of the FMF mutations, and therefore may not have a similar function and/or regulation as the human protein. Supporting this, mice with targeted disruption of the pyrin gene do not show any obvious defects in inflammation (26) , whereas mice with knock-in of humanized pyrin transgenes carrying FMF-associated mutations in the B30.2/SPRY domain show constitutive caspase-1 activation in macrophages and severe inflammation similar to FMF (11). Interestingly, knock-in of a humanized pyrin transgene without FMF-associated mutations leads to embryonic lethality in mice (11) . These observations suggest that the B30.2/SPRY domain regulates the inflammasome activity of human pyrin. The absence of this domain from the mouse pyrin might lead to an altered or even loss of pyrin inflammasome activity. Consistent with that, our studies showed that the expression of mouse pyrin could be upregulated by LPS or IFNγ treatment in peritoneal macrophages (Fig.  5A ). Yet, treatment of these macrophages with anisomycin did not induce caspase-1 activation nor result in IL-1β release, while treatment with the NLRP3 inflammasome activator ATP did both (Fig. 5B) . Our unpublished results also revealed that unlike human pyrin, mouse pyrin does not interact with PSTPIP1, which could explain the recent observations that knock-in of the disease-associated A230T mutant PSTPIP1 in mice does not lead to development of an autoinflammatory disease (31) . Together, these observations further support the idea that mouse pyrin is not activated by the same signaling pathway(s) that activate human pyrin.
In conclusion, we have identified the ribotoxic stress pathway as an important mediator of pyrin inflammasome activation. We propose that activation of p38 MAPK signaling by ribotoxic stress stimulates the recruitment of ASC to the pyrin homotrimer, which induces its oligomerization. It remains to be determined whether p38 MAPK directly phosphorylates the pyrin homotrimer to induce the assembly of the pyrin inflammasome. 
